BR112019002168A2 - anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina - Google Patents
anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudinaInfo
- Publication number
- BR112019002168A2 BR112019002168A2 BR112019002168A BR112019002168A BR112019002168A2 BR 112019002168 A2 BR112019002168 A2 BR 112019002168A2 BR 112019002168 A BR112019002168 A BR 112019002168A BR 112019002168 A BR112019002168 A BR 112019002168A BR 112019002168 A2 BR112019002168 A2 BR 112019002168A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- treatment
- binding
- claudin6
- bispecific trivalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente divulgação proporciona agentes de ligação compreendendo pelo menos três domínios de ligação, em que um primeiro domínio de ligação se liga a um antígeno específico de células t e um segundo domínio de ligação e um terceiro domínio de ligação a uma claudina e métodos de utilização destes agentes de ligação ou ácidos nucleicos que codificam para o tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/072688 WO2018054484A1 (en) | 2016-09-23 | 2016-09-23 | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
PCT/EP2017/073773 WO2018054973A1 (en) | 2016-09-23 | 2017-09-20 | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002168A2 true BR112019002168A2 (pt) | 2019-09-17 |
Family
ID=57003498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002168A BR112019002168A2 (pt) | 2016-09-23 | 2017-09-20 | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina |
Country Status (14)
Country | Link |
---|---|
US (2) | US11787862B2 (pt) |
EP (2) | EP3515939A1 (pt) |
JP (3) | JP7055794B2 (pt) |
KR (2) | KR20230074637A (pt) |
CN (1) | CN110023336B (pt) |
AU (2) | AU2017331331B2 (pt) |
BR (1) | BR112019002168A2 (pt) |
CA (1) | CA3034186A1 (pt) |
IL (3) | IL264233B (pt) |
MX (2) | MX2019003350A (pt) |
NZ (1) | NZ750132A (pt) |
SG (1) | SG11201901899PA (pt) |
WO (2) | WO2018054484A1 (pt) |
ZA (2) | ZA201900962B (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
US11912763B2 (en) | 2018-06-17 | 2024-02-27 | L & L Biopharma Co., Ltd. | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof |
EP3824096A4 (en) * | 2018-07-18 | 2022-04-20 | AskGene Pharma Inc. | NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF |
MA53330A (fr) * | 2018-08-03 | 2021-06-09 | Amgen Inc | Constructions d'anticorps pour cldn18.2 et cd3 |
AU2019391204A1 (en) * | 2018-12-07 | 2021-06-24 | Zlip Holding Limited | Anti-Claudin antibodies and uses thereof |
CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
WO2020156554A1 (zh) * | 2019-02-01 | 2020-08-06 | 科济生物医药(上海)有限公司 | Tcr融合蛋白及表达tcr融合蛋白的细胞 |
CN113767113A (zh) | 2019-02-15 | 2021-12-07 | 因特格尔莫来库乐有限公司 | 密封蛋白6抗体及其用途 |
SG11202109052YA (en) * | 2019-03-29 | 2021-10-28 | Phanes Therapeutics Inc | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
CN113544156B (zh) * | 2019-04-01 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 抗Claudin18.2抗体及其应用 |
KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
CN117659190A (zh) * | 2019-05-16 | 2024-03-08 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
CN113950485A (zh) * | 2019-07-10 | 2022-01-18 | 中外制药株式会社 | 密蛋白-6结合分子及其用途 |
US20220372133A1 (en) * | 2019-07-17 | 2022-11-24 | The Regents Of The University Of California | Claudin18 antibodies and methods of treating cancer |
BR112022017305A2 (pt) * | 2020-03-31 | 2022-10-11 | Chugai Pharmaceutical Co Ltd | Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas |
US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
CA3183565A1 (en) * | 2020-06-30 | 2022-01-06 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
CN114106195A (zh) * | 2020-08-27 | 2022-03-01 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
WO2022100613A1 (zh) * | 2020-11-10 | 2022-05-19 | 上海齐鲁制药研究中心有限公司 | 针对密蛋白18a2和cd3的双特异性抗体及其应用 |
IL305736A (en) * | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
WO2022253248A1 (zh) * | 2021-06-02 | 2022-12-08 | 启愈生物技术(上海)有限公司 | 抗cd3抗体变异体、融合蛋白及应用 |
WO2022266219A1 (en) * | 2021-06-15 | 2022-12-22 | Xencor, Inc. | Heterodimeric antibodies that bind claudin18.2 and cd3 |
WO2022262959A1 (en) * | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
EP4370551A1 (en) * | 2021-07-15 | 2024-05-22 | BioNTech SE | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
WO2023010068A2 (en) * | 2021-07-28 | 2023-02-02 | Cartesian Therapeutics, Inc. | Multiprotein-engineered cells secreting a multispecific antibody |
WO2023185732A1 (zh) * | 2022-03-28 | 2023-10-05 | 信达生物制药(新加坡)有限公司 | 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途 |
WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
WO2024126457A1 (en) * | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
CN116087069B (zh) * | 2023-04-10 | 2023-08-08 | 苏州药明康德新药开发有限公司 | 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体,其制备方法及用途 |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
AU2013347184B2 (en) * | 2012-11-13 | 2018-06-14 | Astellas Pharma Inc. | Agents for treatment of claudin expressing cancer diseases |
US10858415B2 (en) * | 2014-01-29 | 2020-12-08 | Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh | Peptide mimotopes of claudin 18.2 and uses thereof |
EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
CN107001482B (zh) * | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
WO2016097408A1 (en) | 2014-12-19 | 2016-06-23 | Biotecnol Limited | Fusion protein comprising three binding domains to 5t4 and cd3 |
WO2016135239A1 (en) | 2015-02-25 | 2016-09-01 | Biotecnol Limited | Fusion protein comprising three binding domains to her2 |
-
2016
- 2016-09-23 WO PCT/EP2016/072688 patent/WO2018054484A1/en active Application Filing
-
2017
- 2017-09-20 EP EP17776979.1A patent/EP3515939A1/en not_active Withdrawn
- 2017-09-20 AU AU2017331331A patent/AU2017331331B2/en active Active
- 2017-09-20 KR KR1020237017307A patent/KR20230074637A/ko not_active Application Discontinuation
- 2017-09-20 CA CA3034186A patent/CA3034186A1/en active Pending
- 2017-09-20 MX MX2019003350A patent/MX2019003350A/es unknown
- 2017-09-20 BR BR112019002168A patent/BR112019002168A2/pt unknown
- 2017-09-20 JP JP2019515626A patent/JP7055794B2/ja active Active
- 2017-09-20 SG SG11201901899PA patent/SG11201901899PA/en unknown
- 2017-09-20 WO PCT/EP2017/073773 patent/WO2018054973A1/en active Application Filing
- 2017-09-20 CN CN201780056781.8A patent/CN110023336B/zh active Active
- 2017-09-20 KR KR1020197008288A patent/KR102537091B1/ko active IP Right Grant
- 2017-09-20 US US16/335,373 patent/US11787862B2/en active Active
- 2017-09-20 NZ NZ750132A patent/NZ750132A/en unknown
- 2017-09-20 EP EP22160052.1A patent/EP4043494A1/en active Pending
-
2019
- 2019-01-14 IL IL264233A patent/IL264233B/en unknown
- 2019-02-14 ZA ZA2019/00962A patent/ZA201900962B/en unknown
- 2019-03-22 MX MX2023005375A patent/MX2023005375A/es unknown
-
2020
- 2020-05-06 ZA ZA2020/02471A patent/ZA202002471B/en unknown
-
2022
- 2022-01-17 AU AU2022200283A patent/AU2022200283A1/en active Pending
- 2022-01-30 IL IL290230A patent/IL290230A/en unknown
- 2022-01-30 IL IL290234A patent/IL290234A/en unknown
- 2022-04-06 JP JP2022063389A patent/JP7436552B2/ja active Active
-
2023
- 2023-09-15 US US18/468,103 patent/US20240158501A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017454A patent/JP2024054250A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
EA201890390A8 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
CO2017008462A2 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
PH12018500156A1 (en) | Antibody constructs for egfrviii and cd3 | |
PH12018500241A1 (en) | Antibody constructs for dll3 and cd3 | |
CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
EA201890383A8 (ru) | Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3) | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
MX2021005008A (es) | Moduladores de celulas t reguladoras multivalentes. | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
BR112018011100A2 (pt) | anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição. | |
CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
UY38432A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
BR112018075901A2 (pt) | anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro | |
MY195946A (en) | Antibody Constructs for DLL3 and CD3 | |
BR112017002729A2 (pt) | terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025795-0 PROTOCOLO 870220118574 EM 16/12/2022 14:16. |